至今,GenScript的服务及产品已被Cell, Nature, Science, PNAS等1300多家生物医药类杂志引用近万次,处于行业领先水平。NIH、哈佛、耶鲁、斯坦福、普林斯顿、杜克大学等约400家全球著名机构使用GenScript的基因合成、多肽服务、抗体服务和蛋白服务等成功地发表科研成果,再次证明GenScript 有能力帮助业内科学家Make research easy.

A Covalent Calmodulin Inhibitor as a Tool to Study Cellular Mechanisms of K-Ras-Driven Stemness

Front Cell Dev Biol. 2021-07; 
Sunday Okutachi, Ganesh Babu Manoharan, Alexandros Kiriazis, Christina Laurini, Marie Catillon, Frank McCormick, Jari Yli-Kauhaluoma, Daniel Abankwa
Products/Services Used Details Operation
Catalog Peptides Fluorescein-labeled CaMKII and PMCA peptide were from Pepmic, China, and Genscript, United States, respectively Get A Quote

摘要

Recently, the highly mutated oncoprotein K-Ras4B (hereafter K-Ras) was shown to drive cancer cell stemness in conjunction with calmodulin (CaM). We previously showed that the covalent CaM inhibitor ophiobolin A (OphA) can potently inhibit K-Ras stemness activity. However, OphA, a fungus-derived natural product, exhibits an unspecific, broad toxicity across all phyla. Here we identified a less toxic, functional analog of OphA that can efficiently inactivate CaM by covalent inhibition. We analyzed a small series of benzazulenones, which bear some structural similarity to OphA and can be synthesized in only six steps. We identified the formyl aminobenzazulenone , here named Calmirasone1, as a novel and potent cova... More

关键词

BRET, K-Ras, calmodulin, cancer stem cell (CSC), covalent inhibitor